丽珠集团：NS-041片新增“治疗抑郁症”适应症获临床试验批准

Core Viewpoint - Lijun Group's subsidiary, Lijun Pharmaceutical Factory, has received approval from the National Medical Products Administration for clinical trials of NS-041 tablets for the treatment of depression [2] Group 1 - The approval includes a new indication for NS-041 tablets specifically targeting the treatment of depression [2] - The clinical trial approval notification numbers are 2025LP03436 and 2025LP03437 [2]